Author Index to Volume 47

(A) Allen Award address; (ASHG) = American Society of Human Genetics report; (BR) = Book Review; (E) = Editorial; (HGES) = Human Genetics Education section; (L) = Letter to the Editor

Ackford, H., 536 Adelsberger, P. A., 968 Al-Ali, A., 1013 Allen, L., 236, 828 Alpert, E., 583 (L) Amati, P., 904 Amos, C. I., 247, 842 Andermann, E., 815 Anderson, L. L., 952 Angelico, F., 429 Anglani, F., 169 (L) Ankra-Badu, G., 1013 Annerén, G., 595 (BR) Antonarakis, S. E., 968 Antonelli, A., 228 Antonini, R., 429 Apold, J., 1002 Arai, Y., 562 Archer, B. T., III, 551 Arets, A., 196 Arinami, T., 988 Ashton, L. J., 802 Azen, E. A., 686

Bähr-Porsch, S., 656 Baker, E., 187, 493, 802 Bakken, A., 1002 Bale, A. E., 389 Ballabio, A., 664 Barbujani, G., 867 Barr, M., Jr., 745 (BR) Barsh, G., 596 (BR) Bartels, I., 656 Basdevant, A., 721 Bashir, R., 536, 941 Baumiller, R. C., 763 (HGES-BR) Bayleran, J., 815 Bean, B., 351 (L) Beaudet, A. L., 603 (E), 611 Bell, M. V., 181 Berenson, G. S., 247 Berrebi, A., 1013 Berson, E. L., 790

Best, S., 369

Beutler, E., 575, 1008

Bhattacharya, S. S., 536, 935, 941 Bick, D. P., 740 (L) Bingham, E. L., 616 Binkert, F., 968 Bird, A. C., 536 Bird, C. C., 982 Bird, T. D., 915 Bishop, D. F., 784 Black, S. H., 740 (L) Blake, E., 515 Blangero, J., 414 Bloch, M., 4 Bodkin, M., 440 Boehnke, M., 218, 470, 616, 1031 (BR) Bogart, M. H., 353 (L) Bohlman, M. C., 1023 (L) Boman, H., 1002 Bond, A., 13 Bonney, G. E., 247, 542 Bordoni, A., 904 Borecki, I. B., 542 Borgmann, S., 656 Botstein, D., 887 (A) Bottema, C. D. K., 202, 835 Boucher, M. C., 611 Bouhassira, E. E., 161 Boulay, B., 815 Brackmann, H. H., 743 (L) Bradley, D. G., 941 Bresolin, N., 904 Bridge, P. J., 202 Brock, D., 164 (L) Brooks, D. A., 802 Brooks-Wilson, A. R., 952 Brown, A., 454 Brown, B. I., 735 Brown, G. K., 286 Brown, R. M., 286 Brown, W. T., 175 (E) Brunsmann, F., 622 Buchris, V., 20 Buetow, K., 13

Buxbaum, J. M., 127

Callen, D. F., 187, 493, 802 Camporese, C., 169 (L) Capua, A., 815 Carothers, A. D., 165 (L) Carson, N. L., 946 Cerino, A., 228 Chakraborty, R., 87 Chakraborty, S., 37 Chakravarti, A., 635, 644, 926 Chamberlain, J. S., 795 Chance, P. F., 915 Chapman, M., 1 (E) Charmley, P., 860 Chase, C. L., 266 Chen, S.-H., 1020 Chen, Y.-T., 735 Chimera, J., 515 Christianson, R. E., 727 Civelli, O., 828 Claussen, U., 181 Clow, C., 815 Cole, D. E. C., 776 Coleman, M. 935 Concannon, P., 45, 860 Constantinou, C. D., 670 Cophignon, J., 877 (L) Cotton, R. G. H., 279 Couturier, J., 877 (L) Cox, T. M., 101 Craig, I., 935 Cremers, F. P. M., 20, 622 Cross, N. C. P., 101 Crystal, R. G., 403 Cunningham G., 583 (L) Cunningham, G. C., 899 Cystic Fibrosis Genetic Analysis Consortium, The, 354 (L) Dahl, H.-H. M., 279, 286

Davis, J., 896 (E) Dawson, D. V., 842 De Braekeleer, M., 302, 580 (L), 606, 815 De Jonghe, P., 680 Deka, R., 644 de la Chapelle, A., 622 Delattre, O., 877 (L) Del Ben, M., 429 Del Junco, D., 583 (L) Denko, N., 459 Derome, P., 877 (L) Desnick, R. J., 784 De Winter, G., 680 Diala, E. S., 376 Dickens, B., 4 Di Donato, S., 228, 904 DiMartino, N. A., 854 Ding, J.-H., 735 Di Silvestre, D., 706 Dones, I., 228 Donnai, D., 166 (L) Dorsey, B. V., 376 Duband, J. L., 308 Ducat, L., 1029 (L) Duffy, D. L., 590 (L) Dunlop, M. G., 982 Dyer, T. D., 414

Edwards, J. H., 1024 (L)
Egli, H., 743 (L)
Eiben, B., 656
Eiken, H. G., 1002
Eisenbarth, G., 1029 (L)
Elston, R. C., 247, 842
Emi, M., 107, 721
Epstein, C. J., 236, 601 (E)
Erikson, A., 275
Erlich, H. A., 515
Erway, L. G., 760 (HGES-BR)
Esakowitz, L., 536
Evans, H. J., 982
Eyre, H. J., 493, 802

Falls, K., 376
Farrar, G. J., 941
Fedde, K. N., 767, 776
Fefelova, V. V., 294
Ferrell, R. E., 635, 644
Ferretti, L., 228
Fildes, N., 515
Fischel-Ghodsian, N., 1023 (L)

Foellmer, B. E., 483
Folstein, S. E., 362 (BR)
Fontaine, B., 823
Foroud, T., 860
Forrest, S. M., 279
Fox, E. A., 973
Francke, U., 483, 551
Franco, B., 926
Fredriksen, Å., 1002
Freemantle, C. J., 493
Frias, J. L., 167 (L)
Fucharoen, S., 369
Fujita, R., 228
Fujiwara, T. M., 606
Fukuhara, Y., 784

Gadbois, P., 329 Gagné, R., 329, 815 Gail, M. H., 499 Gal, A., 941 Gambert, P., 721 Garcia, C., 926 Garel, L., 338 Garver, K. L., 345 (ASHG) Gatti, R. A., 860 Gatz, G., 656 Geier, M. R., 740 (L) Geisterfer-Lowrance, A. A. T., 389 Gellera, C., 904 Gellert, G., 656 Gheuens, J., 680 Giaccia, A. J., 459 Gieselmann, V., 880 (L) Gilbert, D. A., 499 Ginsburg, D., 616 Glatt, K., 149 Glorieux, F. X., 28 Goebel, R., 656 Goldgar, D. E., 957 Golla, A., 664 Gonzalez, F. J., 994 Goodfellow, P. J., 952 Goodman, H. O., 446, 454 Gorevic, P. D., 127 Gorodezky, C., 515 Grabowski, G. A., 79 Graham, J. M., Jr., 149 Grandy, D. K., 828 Graveline, R., 376 Greenberg, F., 583 (L)

Grenier, A., 325, 329

Groffen, J., 706 Gusella, J. F., 790, 823

Haan, E. A., 493 Hackel, E., 762 (HGES-BR) Hagerman, P. J., 876 (L) Halket, J., 329 Hammans, W., 656 Hanauer, A., 228 Hanioka, N., 994 Hansen, L. L., 286 Hansmann, I., 656 Hanson, M. P., 823 Harris, R., 750 (HGES-L) Hart, I., 459 Haseltine, F. P., 364 (BR) Hata, A., 107, 721 Hauselman, E., 644 Hay, R. J., 499 Hayden, M., 4 Hecht, B. K., 745 (BR) Hecht, F., 745 (BR) Hechtman, P., 815 Hedrick, A., 4 Hegele, R., 107 Helmuth, R., 515 Hentemann, M., 656 Herdman, R. C., 1028 (L) Herndon, C. N., 446 Hesketh, C., 369 Hett, G., 524 Heye, T., 664 Higuchi, R., 515 Hildesheimer, M., 20 Hiller, G., 389 Hilman, B. C., 606 Hirsch, P. C., 1023 (L) Hirschhorn, R., 73, 440 Hirst, M. C., 181 Hoffner, L., 635 Hogan, C., 376 Holden, J. J. A., 20, 395 Hook, E. B., 581 (L), 741 (L) Hopwood, J. J., 187, 802 Hori, K., 562 Horn, G. T., 606 Horsthemke, B., 181 Howell, N., 629 Howells, D. W., 279 Hsieh, C.-L., 483 Huether, C. A., 748 (HGES-E) Huff, V., 155

Huggins, M., 4 Humphries, M. M., 941 Humphries, P., 941 Humphries, S. E., 429 Hyland, V. J., 187

Iida, R., 121 Ikawa, K., 236 Ikehara, Y., 121 Ikeuchi, T., 236 Inglehearn, C. F., 536, 941 Iverius, P.-H., 107, 721

Jackson, C. E., 946
Jacobs, K., 680
Jacobsen, S. J., 376
Jacobson, D. R., 127
Jacquez, G. M., 867
Jansen, R., 808
Jarcho, J. A., 389
Jay, B., 622
Jay, M., 536, 622, 935, 941
Jewell, A. F., 823
Johnston, P. A., 551
Jones, O. W., 353 (L)

Kaback, M. M., 698 Kajihara, S., 562 Kajii, T., 988 Kammerer, C. M., 414 Kanani, S., 4 Kaplan, F., 815 Kaplan, L., 149 Kappler, J., 880 (L) Kasperczyk, A., 854 Kaufman, D. L., 790 Kawashima, H., 236 Keats, B. J. B., 247 Kenna, P., 941 Kerem, B.-s., 606 Ketterling, R. P., 202, 835 Khoury, M. J., 742 (L) Kidd, K. K., 946 Kim, H.-S., 686 Kimura, S., 994 Kishi, K., 121 Kitagawa, T., 562 Kizer, K. W., 899 Klinger, K., 606 Klitz, W., 515 Knoll, J. H. M., 149

Knowles, M. R., 611

Knowlton, R. G., 37 Kobayashi, K., 611 Koch, R., 706 Kochhan, L., 743 (L) Koeberl, D. D., 202 Kolodny, E., 815, 881 (L) Kontusaari, S., 112 Korenberg, J. R., 236 Krontiris, T. G., 854 Kuhl, W., 575, 1008 Kuivaniemi, H., 112 Kuo, C.-Y., 616 Kupper, L. L., 266 Kurdi-Haidar, B., 1013 Kuwano, A., 988 Kwiatkowski, D. J., 62

Laberge, C., 308, 325, 329 Labuda, M., 28 Ladda, R. L., 112 Lafreniere, R. G., 551 Lagerström, M., 275 Lalande, M., 149 Lalouel, J.-M., 107, 721, 915 Lambert, M., 815 Lange, K., 860 Larochelle, J., 302, 338 Latham, T., 79 Lathrop, G. M., 542 Latreille, P., 686 Lebo, R. V., 583 (L) Ledley, F. D., 808 Lehner, T., 20 Lenaerts, C., 338 Lent, K. M., 345 (ASHG) Leone, M., 228 Leppert, M., 915 Lernmark, A., 1029 (L) Lescault, A., 308, 329 Lester, D. H., 536 Leto, T. L., 483 Letter, F., 308 Levilliers, J., 664 Lewis, R. A., 13 Ligi, L., 867 Lillicrap, D. P., 202 Lim, J., 698 Lindsay, S., 935 Lipe, H., 915 Litt, M., 828, 935 Litt, R., 828

Litvak, G., 20

Lomax, K. J., 483 Lorens, J. B., 1002 Luc, G., 721 Luce, M. C., 515 Ludecke, H. J., 181 Ludwig, E. H., 712 Ludwig, M., 742 (L), 941 Lupski, J. R., 926 Lustig, L., 581 (L) Luzzatto, L., 1013 Lynch, A., 4

McAfee, M., 62 McBride, W. O., 389 McCabe, E. R. B., 795 McCarthy, B. J., 712 McClatchey, A. I., 790 MacCluer, J. W., 414 McCullough, D., 629 McFadden, R. R., 171 (BR) McGill, H. C., Jr., 414 McGuffin, P., 524 McKeag, D. B., 753 (HGES) McKenna, W., 389 MacKinnon, R. N., 181 MacLaren, R., 459 McLean, W. T., Jr., 446 McWilliam, P., 941 Maddelena, A., 740 (L) Madej, R., 515 Magenis, E., 236 Magenis, R. E., 149, 828 Majumder, P. P., 644 Malamut, R. I., 926 Malech, H. L., 483 Malhotra, U., 860 Mandel, J.-L., 228 Maragos, C., 286 Marchbanks, R. M., 524 Martin, G. M., 364 (BR) Martin, J. J., 680 Martin, N. G., 137, 590 (L) Martin, R. H., 349 (L) Martiniuk, F., 73, 440 Martuza, R. L., 823 Mason, P. J., 1013 Mathews, J. D., 590 (L) Mazzarella, B., 429 Meadows, A., 155 Mehler, M., 73 Meitinger, T., 664 Mélançon, M. J., 580 (L)

Melancon, S., 815 Meredith, G., 73 Meyer, U. A., 994 Miciak, A., 1024 (L) Miller, N., 429 Minaguchi, K., 686 Mirman, D., 459 Mitchell, A. L., 389 Moggio, M., 904 Montes de Oca-Luna, R., 926 Moraine, C., 664 Morgan, K., 28, 606 Morissette, J., 325, 329 Morris, C. P., 187, 802 Morton, C. C., 389, 973 Mott, G. E., 414 Mukai, T., 562 Mulinare, J., 742 (L) Mulligan, L. M., 395 Murken, J., 664 Myerowitz, R., 169 (L) Myers, S., 952

Nagao, Y., 784 Nagel, R. L., 161 Nakamura, Y., 982 Nanjee, M. N., 429 Navon, R., 881 (L) Neufeld, E. F., 698 Nicholls, R. D., 149 Nikoskelainen, E. K., 95 Nussbaum, R., 13

Oberle, I., 187 O'Brien, S. I., 499 O'Brien, W. E., 611 O'Connell, P., 915 Odland, E., 1002 Oechsli, F. W., 727 Ogasawara, N., 236 Ohashi, H., 988 Oldenburg, J., 743 (L) Olek, K., 743 (10) Olson, J. M., 470 Oostra, B. A., 187 Oppenheim, A., 1013 O'Regan, S., 317 Oshima, A., 784 Osmers, R., 656 Ott, J., 20, 166 (L), 1029 (L) Owada, M., 562

Özçelik, T., 551

Pack, M., 670 Pancoast, I., 454 Pandolfo, M., 228 Pandya, A., 706 Pannacci, M., 904 Papiha, S. S., 536 Paradis, K., 338 Patel, P. I., 926 Paw, B. H., 698 Pawlowitzki, I. H., 622 Pee, D., 499 Permutt, M. A., 1029 (L) Petersen, M. B., 968 Petit, C., 664 Pettersson, U., 275 Philippon, J., 877 (L) Picci, L., 169 (L) Pillers, D.-A. M., 795 Pinckers, A. J. L. G., 622 Plante, M., 308 Poon, R., 395 Potier, M., 815 Powell, B. R., 795 Prentice, R., 255 Prevost, C., 815 Prockop, D. J., 112, 670 Proia, R. L., 881 (L) Propping, P., 880 (L) Pujades, M. A., 575 Pulst, S.-M., 236 Punnett, H. H., 568

Quarrell, O. W. J., 4

Raeymaekers, P., 680 Rainer, J., 795 Ramesh, V., 790 Rao, D. C., 542 Rasmussen, S., 742 (L) Rauskolb, R., 656 Read, A. P., 166 (L) Rediker, K., 376 Redmond, R., 941 Reefer, J., 644 Reid, Y. A., 499 Riccardi, V. M., 155 Ringenbergs, M. L., 493 Rising, M. B., 376 Robertson, M., 107 Robinson, A., 363 (BR) Rocchi, M., 187 Romain, D., 493

Ropers, H.-H., 187, 622 Roses, A. D., 596 (BR) Roth, M. S., 616 Rouleau, G. A., 823, 877 (L) Roy, C. C., 338 Rozen, R., 606 Rubinstein, P., 1029 (L) Russo, P., 317

Sakuraba, H., 784 Salser, W., 860 Samanns, C., 941 Sanal, O., 860 Sandkuyl, L., 20 Sankila, E.-M., 622 Sanson, M., 877 (L) Sato, W., 121 Saunders, G. F., 155 Savill, J., 429 Savontaus, M.-L., 95 Sawazaki, K., 121 Scarlato, G., 904 Schinzel, A., 941, 968 Schmidt, M., 187 Schmill, N., 515 Schonberg, S. A., 236 Schulman, J. D., 740 (L) Schultz, P., 376 Schwaab, R., 743 (L) Schwartz, C. E., 187, 446, 454 Schwartz, M., 622 Schwartz, R. H., 606 Scott, C. R., 1020 Scott, H. S., 802 Scriver, C., 815 Seashore, M. R., 759 (HGES-BR) Seidman, C. E., 389 Seidman, E. G., 338 Seidman, J. G., 389 Seizinger, B. R., 823 Senger, G., 181 Sergeant, M., 524 Servidei, S., 904 Shapiro, L. J., 583 (L) Sharp, E. M., 941 Shih, V. E., 790 Shiloh, Y., 20 Shimmoto, M., 784 Shore, S., 169 (L) Sieving, P. A., 616 Simensen, R. J., 446 Simons, M. J., 583 (L)

Simpson, N. E., 946, 952 Sippell, W. G., 664 Sirugo, G., 228 Slaugenhaupt, S., 926 Smeets, D., 196 Smith, F. I., 79 Smouse, P. E., 761 (HGES-BR) Social Issues Committee, ASHG, 343 (ASHG) Solomon, S. D., 389 Sommer, S. S., 202, 835 Sood, R., 395 Spielman, R. S., 45, 1029 (L) Stamato, T. D., 459 Stambolian, D., 13 Stanislovitis, P., 606 Steel, C. M., 982 Stevenson, R. E., 446, 454 Stoneking, M., 515 Strong, L. C., 155 Südhof, T. C., 551 Surti, U., 635, 644 Sutherland, G. R., 187, 802 Suthers, G. K., 53, 187 Suzuki, K., 568 Suzuki, Y., 784 Swerts, L., 680 Swift, M., 266 Swinford, A. E., 753 (HGES) Sykes, B., 593 (L) Sylvester, D. R., 45

Takahashi, H., 403 Talmud, P. J., 429 Tanaka, A., 568 Tanguay, R. M., 308 Taniguchi, N., 236 ten Kate, L. P., 359 (L) Theilmann, J., 4

Szabo, P., 20

Thein, S. L., 369 Theophilus, B. D. M., 79 Thomas, G., 877 (L) Thomas, I. T., 167 (L) Thomas, N. S., 187 Thompson, E., 255 Tidmarsh, S., 524 Tieu, P. T., 698 Timmerman, V., 680 Tobin, A. J., 790 Torfs, C. P., 727 Towbin, J. A., 795 Treloar, S. A., 137 Tromp, G., 112 Tsui, L.-C., 606 Tsukahara, M., 988 Tzall, S., 73, 440

Ulmer, J., 454

Valet, J. P., 308, 325 Vallee, B. L., 973 Van Broeckhoven, C., 680 van den Berg, B. J., 727 Vandenberghe, A., 680 van de Pol, D. J. R., 622 Villki, J., 95 Vives-Corrons, J.-L., 575 Vosberg, H.-P., 389

Waldren, C., 459
Waller, K., 581 (L)
Wasi, P., 369
Watson, J. E. V., 181
Watty, A., 941
Waurin, J. L., 353 (L)
Weatherall, D. J., 369
Weber, A., 338
Weeks, D. E., 166 (L), 592 (L)
Wei, S., 860

Weiffenbach, B., 376 Weitnauer, L., 228 Wenger, D. A., 37 Weremowicz, S., 973 West, R., 236 Whatley, S., 524 White, B. N., 20, 395 White, C., 499 White, R. L., 892 (A), 982 Whyte, M. P., 767, 776 Weiringa, B., 622 Willard, H. F., 551 Wilson, P. J., 187 Wilson, S. R., 53 Winichagoon, P., 369 Wright, A. F., 536, 622, 935 Wright, J. A., 45 Wright, L. G., 45 Wu, D., 795 Wu, J., 946 Wyllie, A. H., 982

Xu, C.-F., 429

Yamamoto, K., 236 Yang, B.-Z., 735 Yaouanq, J., 542 Yasuda, T., 121 Yoon, H.-S., 835 Young, J. L., 740 (L) Young, M. R., 616 Young, S. B., 670 Youssoufian, H., 62

Zacchello, F., 169 (L) Zeviani, M., 904 Zhao, L. P., 255 Zhou, Q.-Y., 828 Ziv, Y., 20 Zlotogora, J., 37

Subject Index to Volume 47

(E) = Editorial; (HGES) = Human Genetics Education section; (L) = Letter to the Editor

Abortion, spontaneous, cytogenetic analysis, chorionic villi, 656

Acid alpha glucosidase

Allele GAA 2, glycogen and transient gene expression, 440

Deficiency, heterogeneity, 73

Acid β-glucosidase gene, alleles in Gaucher disease, 79 Adenomatous polyposis, familial, polymorphic DNA markers, 982

Affection status, segregation/linkage analysis, genetic hemochromatosis, 542

Åland Island eye disease, deletion mapping, p21, 795 Albinism-deafness syndrome, X-linked, mapping, 20 Aldolase B gene

Nonsense mutation, hereditary fructose intolerance, 562

Partial deletions in herditary fructose intolerance, 101 Alkaline phosphatase

Cultured skin fibroblasts, 776

Normal and hypophosphatasia fibroblasts, 767

Allan-Herndon syndrome

Clinical studies, 446

Xq21 DNA markers, linkage, 454

Allele(s)

Acid alpha glucosidase allele, base-pair substitution, 440

Acid β-glucosidase gene in Gaucher disease, 79 α1-Antitrypsin deficiency, deletion of α1-antitrypsin coding exons, 403

Chromosome 22, meningioma, 877 (L)

Hex A mutant, frequency, Tay-Sachs screening, 698 Minisatellite, diversification, HRAS1 locus, 854

CYP2D6, defective oxidation of drugs, 994 Hex A, frequency, Tay-Sachs screening, 698 Tay-Sachs disease, 815

PRB3 locus, proline-rich gl 8, 686

Allele frequency, HLA-DQa, 515

Allele-specific PCR, hemoglobin C mutation, 1023 (L) Allen Award addresses 1989, 887, 892

 α -Actinin gene, linkage to β -spectrin gene, 62 α/β Locus, T cell receptor, 14q11, 973

α-Galactosidase A gene, point mutations, Fabry disease, 784

α-L-Iduronidase gene, 4p16.3, 802

α Subunit gene, β-hexosaminidase, point mutation, infantile Tay-Sachs disease, 568

al-Antitrypsin

Deficiency allele, deletion of α1-antitrypsin coding exons, 403

Null_{isola di procida}, α1-antitrypsin coding exons, 403 α1-Glycine, substitution by cysteine in COL1A1, osteogenesis imperfecta, 670

Alu-PCR, chromosome 17-retaining hybrids, Charcot-Marie-Tooth disease type 1A gene marker, 926

American Society of Human Genetics

Allen Award addresses, 887, 892 Membership survey results, 345

MSAFP policy statement update, remarks on criticism, 740 (L)

Social Issues Committee report, 343

Amyloidosis, senile systemic, homozygous, transthyretin variant, 127

Aneurysms, familial, inheritance of RNA splicing mutation in COL3A1, 112

Angelman syndrome, DNA markers, 149

Angiogenin gene, 14q11, 973

Anosmia, Xp22.3, 664

Antibodies, thyroid, Down syndrome and other trisomies, 727

Antibody method, BrdUrd, replication patterns of fragile X, 988

Antigen, HLA, distribution, ethnogeny, 286 Apolipoprotein(s)

A-I, dietary environment, 414

AI-CIII-AIV gene cluster, lipoprotein and apolipoprotein levels, 429

B

Gene loci, lipoprotein and apolipoprotein levels, 429

Mutation, haplotype analysis, 712

B100, familial defective, apo B mutation, 712

Appendectomy, twins, 590 (L)

Ataxia-telangiectasia locus, mapping, 11q23, 860

Base-pair substitution, acid alpha glucosidase allele, 440 β^s Chromosomes, Bantu haplotype, deletion, 161

β-Hexosaminidase α subunit gene, point mutation, infantile Tay-Sachs disease, 568

 β -spectrin gene, linkage to α -actinin gene, 62

β-Thalassemia, prenatal diagnosis, 369

Birth defects, 741 (L), 742 (L) Books reviewed, author(s)/editor(s):

Boyd, G. W., 745

Burch, J. E., 364

Burnham, D., 763 (HGES)

Chesters, M. S., 364

Clark, A. G., 761 (HGES)

Clegg, M. T., 762 (HGES)

Comings, D. E., 362, 363

Elston, R. C., 1031

Fodden, M., 763 (HGES)

Fristrom, J. W., 762 (HGES)

Gilbert, S. G., 760 (HGES)

Gordon, S., 763 (HGES)

Grumbach, M. M., 595

Harper, P. S., 596

Hartl, D. E., 761 (HGES)

Hodge, S. E., 1031

Hubbard, R., 364, 763 (HGES)

Hughley, B., 763 (HGES)

Lowe, M., 763 (HGES)

Lyon, M. F., 596

MacCluer, J. W., 1031

Mange, A. P. and E. J., 759 (HGES)

Office of Technology Assessment, Congress of the

United States, 171 Persaud, P. V. N., 745

Rosenfeld, R. G., 595

Rosoff, B., 763 (HGES)

Russell, P. J., 762 (HGES)

Searle, A. G., 596

Spence, M. A., 1031

Tobach, E., 763 (HGES)

Vroman, G., 763 (HGES)

Books reviewed, title:

Biological Basis of Disease: Selected Papers by P. R. J. Burch, The, 364

Environmental Causes of Human Birth Defects, 745 Genes and Gender I, 763 (HGES)

Genes and Gender II: Pitfalls in Research on Sex and

Gender, 763 (HGES)
Genes and Gender III: Genetic Determinism and Children, 763 (HGES)

Genes and Gender IV: The Second X and Women's Health, 763 (HGES)

Genes and Gender V: Socialization toward Inequity, 763 (HGES)

Genes and Gender VI: The Gendered Face of Peace and War: A Challenge to Genetic Determinism, 763 (HGES)

Genetic Strains and Variants of the Laboratory Mouse, 2d ed., 596

Genetics, 2d ed., 762 (HGES)

Genetics: Human Aspects, 759 (HGES)

Myotonic Dystrophy, 2d ed., 596

New Developments in Biotechnology, 171

On Stress, Disease and Evolution, 745

Pictorial Human Embryology, 760 (HGES)

Politics of Women's Biology, The, 364

Principles of Genetics, 2d ed., 761 (HGES)

Principles of Population Genetics, 2d ed., 761 (HGES)

Progress in Clinical and Biological Research, vol. 329: Multipoint Mapping and Linkage Analysis Based upon Affected Pedigree Members: Genetic Analysis Workshop 6, 1031

Tourette Syndrome and Human Behavior, 362, 363

Turner Syndrome, 595

BrdUrd antibody method, replication patterns of fragile X, 988

Carcinoma, medullary thyroid with parathyroid tumors, chromosome 10, 946

Cardiac myosin heavy chain genes, cardiomyopathy, 389 Cardiomyopathy, familial hypertrophic, CRI-L436 and CRI-L329 genes, 389

Carrier screening

Cystic fibrosis, 603 (E), 740 (L)

Autosomal recessive diseases, 359 (L)

Ethics, 580 (L)

Cell lines, family, research, 1029 (L)

Charcot-Marie-Tooth disease

Type I, genetic linkage and heterogeneity, 915

Type 1A

Chromosome 17p11.2-p12, 680

Gene marker, 926

Chimerism, pigmentary anomalies, 166 (L), 167 (L) Chorionic villi, cytogenetic analysis, spontaneous abor-

tion, 656

Choroideremia, classical, deletions, 622

Chromosomal mosaicism, pigmentary anomalies, 166 (L), 167 (L)

Chromosome 1, markers, mapping, ovarian teratoma, 644

Chromosome 1q25, autosomal recessive chronic granulomatous disease, 483

Chromosome 4p16.3, α-L-iduronidase gene, 802

Chromosome 5

Familial adenomatous polyposis, DNA markers, 982 Human, double-strand break-repair deficiency and gamma-ray sensitivity in XR-1 hamster variant, 459

Chromosome 5q11-q13, schizophrenia susceptibility gene, 524

Chromosome 5q35.1, D₁ dopamine receptor gene, 828

Chromosome 7q11.23, autosomal recessive chronic granulomatous disease, 483

Chromosome 10, centromere, medullary thyroid carcinoma with parathyroid tumors, 946

Chromosome 11p13, de novo constitutional deletions,

Chromosome 11q23, ataxia-telangiectasia locus, mapping, 860

Chromosome 12q14, autosomal recessive vitamin D dependency type I, 28

Chromosome 14, Krabbe disease, 37

Chromosome 14q11, angiogenin gene, 973

Chromosome 14q11-q12, CRI-L436 and CRI-L329 genes, cardiomyopathy, 389

Chromosome 15q11q13, DNA markers, Angelman syndrome, 149

Chromosome 17p11.2-p12, Charcot-Marie-Tooth neuropathy type 1A, 680

Chromosome 21, Down syndrome phenotype, 236 Chromosome 22, alleles, meningioma, 877 (L)

Chromosome 22, losses, sporadic meningioma, 823

Chromosome X, synaptophysin, 551

Chromosome Xp, microsatellite probe DXS426, 935 Chromosome Xp21, deletion mapping, Åland Island

eye disease, 795

Chromosome Xq21, DNA markers, Allan-Herndon syndrome, linkage, 454

Chromosome Xp21.1-Xp22.3, Nance-Horan syndrome, 13

Chromosome Xp22.1-p22.3, probes, X-linked juvenile retinoschisis, 616

Chromosome Xp22.3, X-linked Kallman syndrome, 664

Chromosome Xq26-Xq28, DNA markers, genetic mapping, fragile X, 395

Chromosome Xq26.3-q27.1, X-linked albinismdeafness syndrome, 20

Clines, multilocus, gene frequency diversity, 867 Cloning

a-Actinin gene, cytoskeletal, 62

cDNA, PCR, methylmalonic acidemia, 808 CYP2D locus, defective oxidation of drugs, 994

CYP2D6 mutant allele, defective oxidation of drugs,

Cysteine, substitution for α1-glycine 904 in COL1A1, osteogenesis imperfecta, 670

Cystic fibrosis

Carrier screening, 359 (L), 603 (E), 740 (L) Ethics, 580 (L)

Gene, benign missense variations, 611 Mutations, 606

Population screening, 164 (L)

Risk analysis, slash sheet, 1024 (L)

Cystic Fibrosis Genetic Analysis Consortium, ΔF508 mutation, survey, 354 (L)

Cytogenetic analysis

Direct-preparation method, spontaneous abortion, 656

Isochromosome 18p syndrome, 493 Ovarian teratoma, 635

D₁ dopamine receptor gene, 5q35.1, EcoRI RFLP, 828 D3S47, autosomal dominant retinitis pigmentosa, linkage, 536

D9S5, linkage disequilibrium with Friedreich ataxia, 228

D9S15, linkage disequilibrium with Friedreich ataxia, 228

D10S94, multiple endocrine neoplasia type 2A, 952 Deletion(s)

α1-Antitrypsin coding exons, α1-antitrypsin deficiency allele, 403

β^s Chromosomes, Bantu haplotype, 161

Classical choroideremia, 622

De novo constitutional, chromosome 11p13, 155 Factor IX_{Seattle 1}, 1020

Mapping, Åland Island eye disease, Xp21, 795

Mutations causing hemophilia B, 202 Nucleus-driven large-scale, mitochondrial genome,

Partial, aldolase B gene in hereditary fructose intolerance, 101

Repeat sequence, E1α gene, PDH deficiency, 286 ΔF508 mutation, survey, 354 (L)

Deoxyribonuclease, serum, polymorphism, 121 Diabetes mellitus, insulin-dependent, T-cell receptor genes, 45

Diagnosis

Cytogenetic, isochromosome 18p syndrome, 493 Prenatal

β-Thalassemia, 369

Type III glycogen storage disease, 735

Diagnostic tests, DNA, clinical care, 583 (L)

Dietary environment, apo A-I, 414

Dihydropteridine reductase deficiency, threonine, 279
Disease, autosomal recessive, carrier screening, 359 (L)
Disequilibrium, linkage, D9S5 and D9S15 and
Friedreich ataxia, 228

DNA

Complementary, cloning, PCR, methylmalonic acidemia, 808

Diagnostic tests, clinical care, 583 (L)

Double-strand break-repair deficiency and gamma-ray sensitivity, XR-1 hamster variant, 459

Fingerprints, cell-line individualization, 499 Haplotype analysis, hyperphenylalaninemia, 706 Marker(s)

Chromosome 15q11q13, Angelman syndrome, 149 D10S94, multiple endocrine neoplasia type 2A,

Polymorphic, genetic linkage map for familial adenomatous polyposis, 982

Xq21, Allan-Herndon syndrome, linkage, 454 Xq26-Xq28, genetic mapping, fragile-X locus, 395 Mitochondrial, polymorphism and heterogeneity, 87 Polymorphisms, de novo dup(21q) in Down syndrome, 968

Probes near FRAXA, physical mapping, 187 Typing, forensic medicine, 876 (L)

Dopamine receptor gene D₁, 5q35.1 EcoRI, 828 Double-strand break-repair deficiency, DNA, XR-1 hamster variant, 459

Down syndrome

De novo dup (21q), 968

Detection, gestational age, 581 (L), 583 (L)

DNA polymorphisms, 968

Phenotype, chromosome 21, 236

Thyroid antibodies as risk factor, 727

Drug oxidation, defective, CYP2D locus, 994 dup (21) Chromosomes, de novo, Down syndrome, 968 DXS426, microsatellite probe, X-linked retinitis pig-

mentosa, 935

E1α gene, repeat sequence deletion, pyruvate dehydrogenase deficiency, 286

Education, medical school curriculum, genetics, 748 (HGES-E), 753 (HGES)

Survey, 750 (HGES)

Ehler-Danlos syndrome type IV, familial aneurysms, 112 Endocrine neoplasia, multiple type 2A, D10S94, 952 Enzymatic amplification, allele and genotype frequencies, HLA-DQα, 515

Epidemiology, genetic, hereditary tyrosinemia, 302 Ethical/legal issues

Cystic fibrosis carrier screening, 580 (L)

Linkage analysis in Huntington disease, 1 (E) Predictive testing, adult-onset disease, 4

Ethnogeny, HLA antigen distribution, 294 Etiology, senile systemic amyloidosis, 127

Fabry disease, hemizygotes, α-Gal A point mutations, 784

Facioscapulohumeral muscular dystrophy, linkage

analysis, 376

Factor VIII, gene point mutations, hemophilia A, 743 (L)

Factor IX, germ-line mutation pattern, 835

Factor IX_{Seattle 1}, gene deletion by recombination, 1020 Family cell lines, research, 1029 (L)

Fibroblast(s)

Cultured skin, alkaline phosphatase, 776 muto methylmalonic acidemia, heterozygous mutations, 808

Normal and hypophosphatasia, alkaline phosphatase, 767

Forensic medicine, DNA typing, 876 (L)

Fragile-site expression, genetic determination, 196 Fragile X, 175 (E)

DNA probes near, 187

Microdissection, 181

Replication patterns in heterozygous carriers, 988 Xq26-Xq28, DNA markers, 395

Friedreich ataxia, genetic homogeneity and linkage disequilibrium with D9S5 and D9S15, 228

Fructose intolerance, hereditary

Nonsense mutation, aldolase B gene, 562 Partial aldolase B gene deletions, 101

Fumarylacetoacetate, hereditary tyrosinemia type I, mass screening, 325

Fumarylacetoacetate hydrolase deficiency, hereditary tyrosinemia, 308

G₁₉₃₄→A, mutant CYP2D6 allele, defective oxidation of drugs, 994

Gamma-ray sensitivity, XR-1 hamster variant, 459 Gaucher disease

Acid β-glucosidase gene alleles, 79

Type III, glucocerebrosidase gene mutation, 275

Gene-disease associations, testing, 266

Genetic counseling, rare syndromes, 53

Genetic epidemiology, hereditary tyrosinemia, 302 Genetic heterogeneity, autosomal dominant retinitis pigmentosa, 536

Genetic linkage, mapping of Krabbe disease, 37 Genetic mosaicism, pigmentary anomalies, 166 (L), 167 (L)

Genomic imprinting, absence in sporadic meningioma, 823

Genotype frequency, HLA-DQa, 515

Germ-line mutation pattern, factor IX, 835

Gestational age, MSAFP screening and Down syndrome detection, 581 (L), 583 (L)

Glucocerebrosidase gene mutation, Gaucher disease type III, 275

Glucose-6-phosphate dehydrogenase

Andulus 1361A, 575

Mediterranean, 1008, 1013

Molecular genetics, 575

NT 1311 polymorphisms, 1008

Glycogen storage disease, type III, prenatal diagnosis, 735

Glycoprotein, disulfide-bonded salivary proline-rich, PRB3 alleles, 686

Granulomatous disease, chronic autosomal recessive, gene assigment, 483

Gyrate atrophy, ornithine aminotransferase locus, splicing defect, 790

Haplotype

Bantu, deletion in Bs chromosomes, 161

7, phenylketonuria genes, termination mutation,

Haplotype analysis

apo B mutation and familial defective apo B100, 712 DNA, hyperphenylalaninemia, 706

Hemizygotes, Fabry disease, α-Gal A point mutations, 784

Hemochromatosis, genetic, segregaton/linkage analysis, 542

Hemoglobin C mutation, allele-specific PCR, 1023 (L)

Hemophilia A, clinical manifestations, FVIII point mutations, 743 (L)

Hemophilia B, mutations, 202

Heteroduplexes

Formation in PCR, 169 (L)

PCR-generated in Tay-Sachs carriers, 169 (L)

Heterogeneity

Acid alpha glucosidase deficiency, 73

Charcot-Marie-Tooth disease type I, 915

Genetic, autosomal dominant retinitis pigmentosa, 536

mtDNA polymorphism, 87

Phenotypic, osteogenesis imperfecta, 670

Risk calculation, 165 (L)

Heterozygote, compound, lipoprotein lipase deficiency, 721

Heterozygous carriers, replication patterns of fragile X, 988

Heterozygous mutations, muto methylmalonic acidemia fibroblasts, 808

Hex A mutant alleles, frequency, Tay-Sachs screening, 698

Hexosaminidase, pseudodeficiency, 880 (L), 881 (L) History, genetics, 601 (E)

HLA, segregation/linkage analysis, genetic hemochromatosis, 542 HLA antigen distribution, ethnogeny, 286

HLA-DQa allele, frequency, 515

Homogeneity, genetic, Friedreich ataxia, 228

HRASI locus, minisatellite allele diversification, 854 Huntington disease

Linkage analysis, ethical/legal isues, 1 (E)

Predictive testing, ethical/legal issues, 4

Hybrids, chromosome 17-retaining, Alu-PCR, Charcot-Marie-Tooth disease type 1A gene marker, 926

Hydridization, in situ, cytogenetic diagnosis, isochromosome 18p syndrome, 493

Hyperphenylalaninemia, DNA haplotype analysis, 706 Hypervariable repeat sequence CRI-S232, X-linked Kallman syndrome, 664

Hypogonadism, hypogonadotropic, Xp22.3, 664 Hypophosphatasia, fibroblasts, alkaline phosphatase,

Identity-by-descent sharing, relatives, probabilities, 842 Imprinting, genomic, absence in sporadic meningioma, 823

Inheritance, RNA splicing mutation in COL3A1, 112 Insertion mutation, Tay-Sachs carriers, PCR-generated heteroduplexes, 169 (L)

Interference coefficients, multilocus linkage analysis, 255

Isochromosomes, de novo dup(21q) in Down syndrome, 968

Isochromosome 18p syndrome, cytogenetic diagnosis, 493

Isoenzyme, tissue nonspecific, alkaline phosphatase, 767

Isozymes, pattern similarities in serum, urine, and organs, 121

Kallman syndrome, X-linked, X-22.3, 664 Krabbe disease, mapping by genetic linkage, 37

Landouzy-Déjérine muscular dystrophy, linkage analysis, 376

Leber hereditary optic neuropathy, absence of mitochondrial ND4 gene mutation, 629

Leber hereditary optic neuroretinopathy, segregation of mitochondrial genomes, 95

Legal/ethical issues

Linkage analysis in Huntington disease, 1 (E)

Predictive testing, adult-onset disease, 4

Linkage

Affected sib pairs, 45

Allan-Herndon syndrome and Xq21 DNA markers, 454

α-Actinin gene and β-spectrin gene, 62

Autosomal dominant retinitis pigmentosa and D3S47, 536

Genetic

Detection by multivariate method, 247 Type I Charcot-Marie-Tooth disease, 915

Genetic map

DNA markers for familial adenomatous polyposis, 982

Krabbe disease, 37

Microsatellite probe DXS426 and X-linked retinitis pigmentosa, 935

Osteogenesis imperfecta and COL1A1 and COL1A2, 592 (L), 593 (L)

X-linked

Juvenile retinoschisis and Xp22.1-p22.3 probes, 616

Kallman syndrome and CRI-S232, 664

Linkage analysis

Dominant locus for quantitative trait, lod score method, 218

Facioscapulohumeral muscular dystrophy, 376 Genetic hemochromatosis, 542

Huntington disease, ethical/legal issues, 1 (E)

Localization of Nance-Horan syndrome, 13

Mapping autosomal recessive vitamin D dependency type I, 28

Multilocus, recombination fractions and interference coefficients, 255

Linkage disequilibrium, D9S5 and D9S15 and Friedreich ataxia, 228

Lipoprotein, apo AI-CIII-AIV gene cluster and apo B gene loci, 429

Lipoprotein lipase

Deficiency

Compound heterozygote, 721

Nonsense mutation in LPL gene, 107

Gene

AG→AA transition, 721

Nonsense mutation, 107

Lipoprotein phenotype, detection of genetic linkage by multivariate method, 247

Map/mapping

Ataxia-telangiectasia locus, 11q23, 860

Autosomal recessive vitamin D dependency type I, 28 Chromosome 1 markers, ovarian teratoma, 644

Deletion, Åland Island eye disease, Xp21, 795 Genetic, Xq26-Xq28 DNA markers, fragile-X

Genetic, Xq26-Xq28 DNA markers, fragile-X locus, 395

Genetic linkage

DNA markers for familial adenomatous polyposis, 982

Krabbe disease, 37

Physical, DNA probes near FRAXA, 187

X-linked albinism-deafness syndrome, 20

Marker(s)

Charcot-Marie-Tooth disease type 1A gene, 926

Chromosome 1, gene-centromere mapping, ovarian teratoma, 644

DNA

Chromosome 15q11q13, Angelman syndrome, 149 D10S94, multiple endocrine neoplasia type 2A, 952

Polymorphic, genetic linkage map for familial adenomatous polyposis, 982

Xq21, Allan-Herndon syndrome, linkage, 454 Xq26-Xq28, genetic mapping, fragile-X locus, 395

Loci D9S5 and D9S15, linkage disequilibrium with Friedreich ataxia, 228

Nonsytenic loci COLIA1 and COLIA2, OI linkage, 593 (L), 593 (L)

Maternal serum alpha-fetoprotein

Policy statement update, remarks on criticism, 740 (L) Screening

Gestational age, 581 (L), 583 (L)

State health agencies, 899

State activities, 896 (E)

Medical school curriculum, genetics, 748 (HGES-E), 753 (HGES)

Survey, 750 (HGES)

Medullary thyroid carcinoma with parathyroid tumors, chromosome 10, 946

Membership survey results, American Society of Human Genetics, 345

Menarche, age as fitness trait, 137

Meningioma

Chromosome 22 alleles, 877 (L)

Sporadic, chromosome 22 losses, 823

Methylmalonic acidemia, mut°, fibroblast heterozygous mutations, 808

Microsatellite probe DXS426, X-linked retinitis pigmentosa, 935

Minisatellite allele diversification, HRAS1 locus, 854 Missense variations, benign, cystic fibrosis gene, 611 Mitochondrial DNA, polymorphism and heterogeneity, 87

Mitochondrial genome(s)

Nucleus-driven large-scale deletions, 904

Segregation in Leber hereditary optic neuroretinopathy, 95

Mitochondrial ND4 gene, mutation, absence in Leber hereditary neuropathy, 629

Monte Carlo comparison, ordering multiple loci, 470 Mosaicism, chromosomal and genetic, pigmentary

anomalies, 166 (L), 167 (L)

Multilocus clines, gene frequency diversity, 867

Multilocus linkage analysis, recombination fractions and interference coefficients, 255

Multipoint analysis, quantitative variation, 957

Muscular dystrophy, facioscapulohumeral, linkage analysis, 376

Mutation(s)

apo B, haplotype analysis, 712

Cystein for α1-glycine 904 in COL1A1, osteogenesis imperfecta, 670

Cystic fibrosis, 606

ΔF508, survey, 354 (L)

Familial defective apo B100, 712

Fragile X, DNA probes near, 187

Germ line, factor IX, 835

Glucose-6-phosphate dehydrogenase Mediterranean, 1008

Hemoglobin C, allele-specific PCR, 1023 (L)

Hemophilia B, 202

Heterozygous, muto methylmalonic acidemia fibroblasts, 808

Insertion, Tay-Sachs carriers, PCR-generated heteroduplexes, 169 (L)

Medullary thyroid carcinoma with parathyroid tumors, chromosome 10, 946

Mitochondrial ND4 gene, absence in Leber hereditary neuropathy, 629

Nonsense

Aldolase B gene, hereditary fructose intolerance, 562

Lipoprotein lipase gene, 107

Point

α-Galactosidase A gene, Fabry disease, 784 β-Hexosaminidase α subunit gene, infantile Tay-

Sachs disease, 568

FVIII gene, hemophilia A, 743 (L) RNA splicing, inheritance, 112

Termination, haplotype 7 phenylketonuria genes,

mut^o methylmalonic acidemia, fibroblast heterozygous mutations, 808

Nance-Horan syndrome, localization by linkage analysis, 13

Neoplasia, multiple endocrine type 2A, D10S94, 952 Neuropathy

Charcot-Marie-Tooth type 1A, chromosome 17p11.2p12, 680

Leber hereditary optic, absence of mitochondrial ND4 gene mutation, 629

Motor and sensory, type I hereditary, genetic linkage

and heterogeneity, 915

Neuroretinopathy, Leber hereditary optic, segregation of mitochondrial genomes, 95

New Developments in Biotechnology, critique of book review, 1028 (L)

Nondisjunction, origin, ovarian teratoma, 644

Nonsense mutation

Aldolase B gene, hereditary fructose intolerance, 562 Lipoprotein lipase gene, 107

Nonsytenic marker loci, CO1A1 and COL1A2, osteogenesis imperfecta linkage, 592 (L), 593 (L)

NT 1311 polymorphism, glucose-6-phosphate dehydrogenase, 1008

Oligonucleotide probes, allele and genotype frequencies, HLA-DQα, 515

Ornithine aminotransferase locus, splicing defect, gyrate atrophy, 790

Osteogenesis imperfecta, phenotypic heterogeneity, 670 Ovarian teratoma, cytogenetic analysis and mechanism origin, 635, 644

Pathology, visceral, hereditary tyrosinemia type I, 317 Pedigree, linkage, resampling method for confidence interval, 53

Phenotype

Down syndrome, 236

Lipoprotein, detection of genetic linkage by multivariate method, 247

Phenylketonuria, haplotype 7 genes, termination mutation, 1002

Phosphoethanolamine, alkaline phosphatase, 767 Pigmentary anomalies, mosaicism and chimerism, 166 (L), 167 (L)

Point mutation(s)

α-Galactosidase A gene, Fabry disease, 784 β-Hexosaminidase α subunit gene, infantile Tay-Sachs

disease, 568 FVIII gene, hemophilia A, 743 (L)

Policy statement update, MSAFP, remarks on criticism, 740 (L)

Polymerase chain reaction

Allele-specific, hemoglobin C mutation, 1027

Alu, chromosome 17-retaining hybrids, Charcot-Marie-Tooth disease type 1A gene marker, 926 cDNA cloning, methylmalonic acidemia, 808

Generation of heteroduplexes from Tay-Sachs carriers, 169 (L)

Heteroduplex formation, 169 (L)

Polymorphism(s)

DNA, de novo dup(21q) in Down syndrome, 968 mtDNA, heterogeneity, 87

NT 1311, glucose-6-phosphate dehydrogenase, 1008 Restriction-fragment-length, *Eco*RI, DRD1, 828 Serum deoxyribonuclease, 121

Polyposis, familial adenomatous, polymorphic DNA markers, 982

Population screening, cystic fibrosis, 164 (L) *PRB3* locus, alleles, proline-rich gl 8, 686 Predictive testing, adult-onset disease, 1 (E)

Ethical/legal issues, 4
Pregnancy wastage, cytogenetic analysis, spontaneous abortion, 656

Prenatal diagnosis

β-Thalassemia, 369

Glycogen storage disease type III, 735

Procollagen gene, RNA splicing mutation, inheritance, 112

Procollagen type I gene, mutation, cystein for α1-glycine, osteogenesis imperfecta, 670

Proline→histidine substitution, rhodopsin, absence in autosomal dominant retinitis pigmentosa, 941

Pseudodeficiency, hexosaminidase, 880 (L), 881 (L) Pseudohypophosphatasia, alkaline phosphatase, 776 Pyridoxal-5'-phosphate ectophosphatase, alkaline phosphatase, 767

Pyruvate dehydrogenase deficiency, E1α gene, repeat sequence deletion, 286

Quantitative trait, linkage analysis of dominant locus, 218

Quantitative variation, multipoint analysis, 957

Recombination, gene deletion in factor IX_{Seattle 1}, 1020 Recombination fraction, multilocus linkage analysis, 255

Recurrence risks, live births and "stillbirths," 741 (L), 742 (L)

Replication patterns, fragile X in heterozygous carriers, 988

Restriction-fragment-length polymorphism, EcoRI, DRD1, 828

Retinitis pigmentosa

Autosomal dominant

Absence of rhodopsin pro→his substitution, 941 D3S47 linkage, 536

X-linked, microsatellite probe DXS426, 935

Retinoschisis, X-linked juvenile, Xp22.1-p22.3 probes, linkage, 616

Rhodopsin, proline→histidine substitution, absence in ADRP, 941

Risk

Calculation under heterogeneity, 165 (L) Genetic, support intervals, 166 (L) Risk analysis, cystic fibrosis, slash sheet, 1024 (L) Risk factor, thyroid antibodies, Down syndrome and other trisomies, 727

RNA splicing mutation, COL3A1, inheritance, 112

Salivary proline-rich glycoprotein, disulfide bonded, PRB3 alleles, 686

Schizophrenia, susceptibility gene, chromosome 5q11q13, 524

Screening

Carrier

Cystic fibrosis, 603 (E), 740 (L) Autosomal recessive disease, 359 (L) Ethics, 580 (L)

Hereditary tyrosinemia type I, fumarylacetoacetate, 325

Maternal serum alpha-fetoprotein Gestational age, 581 (L), 583 (L)

State health agencies, 899

Patent of test, 353 (L) Population, cystic fibrosis, 164 (L)

Tay-Sachs disease, Hex A mutant alleles frequency,

Segregation, mitochondrial genomes in Leber hereditary optic neuroretinopathy, 95

Segregation analysis, genetic hemochromatosis, 542 Sex ratio

Progenitive, sperm cells, 351 (L)

Sperm cells, 349 (L)

Sib pairs, affected, linkage, 45

Slash sheet, risk analysis in cystic fibrosis, 1024 (L) Social Issues Committee report, American Society of Human Genetics, 343

Sperm cells

Progenitive sex ratio, 351 (L)

Sex ratio, 349 (L)

Splicing defect, ornithine aminotransfere locus, gyrate atrophy, 790

Splicing mutation, RNA, inheritance, 112

Support intervals, genetic risk, 166 (L)

Synaptophysin, gene structure/assignment, 551

T-cell receptor α/β locus, 14q11, 973

T-cell receptor genes, insulin-dependent diabetes mellitus, 45

Tay-Sachs disease

Infantile

β-Hexosaminidase α subunit gene, point mutation, 568

Mutant alleles, 815

PCR-generated heteroduplexes, 169 (L)

Screening, Hex A mutant alleles frequency, 698

Teratoma, ovarian, cytogenetic analysis and mechanism of origin, 635, 644

Termination mutation, haplotype 7 phenylketonuria genes, 1002

Threonine, dihydropteridine reductase deficiency, 279 Thyroid antibodies, Down syndrome and other trisomies, 727

Thyroid carcinoma, medullary with parathyroid tumors, chromosome 10, 946

Transient gene expression, acid alpha glucosidase allele, 440

Transition(s)

Lipoprotein lipase deficiency, 721 Mutations causing hemophilia B, 202

Translocations, de novo dup(21q) in Down syndrome, 968

Transplantation, liver, hereditary tyrosinemia, 338 Transthyretin variant, homozygous, senile systemic amyloidosis, 127

Transversions, mutations causing hemophilia B, 202 Trisomy, thyroid antibodies as risk factors, 727 Tumors, parathyroid, medullary thyroid carcinoma, 946

Age at menarche as fitness trait, 137

Appendectomy, 590 (L)

Tyrosinemia, hereditary

Fumarylacetoacetate hydrolase deficiency, 308

Genetic epidemiology, 302 Liver transplantation, 338

Type I

Homogentisic acid, oral loading, 329 Screening, fumarylacetoacetate, 325 Visceral pathology, 317

Vitamin D dependency type I, autosomal recessive, mapping, 28

X-linked albinism-deafness syndrome, mapping, 20 X-linked juvenile retinoschisis, Xp22.1-p22.3 probes, linkage, 616

X-linked Kallman syndrome, Xp22.3, 664

X-linked retinitis pigmentosa, microsatellite probe DX\$426, 935

Xr-1 hamster variant, DNA double-strand break-repair deficiency and gamma ray sensitivity, 459

